Consultant Plastic Surgeon, School of Health Sciences, Birmingham City University, Birmingham, UK.
J Wound Care. 2023 Jan 1;32(Sup2):S11-S19. doi: 10.12968/jowc.2023.32.Sup2.S11.
There is a clear scientific rationale for using cellular, acellular and matrix-like products (CAMPs), such as small intestinal submucosa extracellular matrix (SIS-ECM), in hard-to-heal wounds, such as diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers and arterial leg ulcers. The clinical evidence supporting the use of SIS-ECM has grown over the past several decades. This evidence base now encompasses a wide range of hard-to-heal wound indications, including DFUs and VLUs, as well as increasingly complex acute wound indications, such as delayed postoperative wounds, traumatic wounds and burns. The aim of this article is to review the steadily amassed body of evidence that describes the clinical outcomes associated with treatment with SIS-ECM and its potential implications for the overall costs of treatment.
使用细胞、去细胞和类似基质的产品（CAMPs），如小肠黏膜下层细胞外基质（SIS-ECM），在难以愈合的伤口中具有明确的科学依据，如糖尿病足溃疡（DFUs）、静脉性腿部溃疡（VLUs）、压疮和动脉性腿部溃疡。过去几十年中，支持使用 SIS-ECM 的临床证据不断增加。该证据基础现在涵盖了广泛的难以愈合的伤口适应症，包括 DFUs 和 VLUs，以及越来越复杂的急性伤口适应症，如延迟术后伤口、创伤性伤口和烧伤。本文的目的是回顾不断积累的证据，描述与 SIS-ECM 治疗相关的临床结果及其对治疗总体成本的潜在影响。
